| First Author | Xie W | Year | 2022 |
| Journal | Sci Adv | Volume | 8 |
| Issue | 39 | Pages | eabo4250 |
| PubMed ID | 36179018 | Mgi Jnum | J:329897 |
| Mgi Id | MGI:7355676 | Doi | 10.1126/sciadv.abo4250 |
| Citation | Xie W, et al. (2022) Regulation of autoimmune disease progression by Pik3ip1 through metabolic reprogramming in T cells and therapeutic implications. Sci Adv 8(39):eabo4250 |
| abstractText | Metabolic alterations could profoundly affect immune functions and influence the progression and outcome of autoimmune diseases. However, the detailed mechanisms and their therapeutic potential remain to be defined. Here, we show that phosphatidylinositide 3-kinase interacting protein 1 (Pik3ip1), a newly identified negative immune regulator, is notably down-regulated in several major autoimmune diseases through a previously unidentified mechanism mediated by interleukin-21/p38 mitogen-activated protein kinase/a disintegrin and metalloprotease-17 (ADAM17) pathway. Down-regulation of Pik3ip1 in T cells causes a major metabolic shift from oxidative phosphorylation toward aerobic glycolysis, leading to their overactivation and aggressive disease progression in experimental autoimmune encephalomyelitis (EAE) mouse model. Suppression of hypoxia-inducible factor 1alpha (Hif1alpha) or pharmacologic inhibition of glycolysis could reverse these phenotypes and largely mitigate EAE severity. Our study reveals a previously unrecognized role of Pik3ip1 in metabolic regulation that substantially affects the inflammatory loop in the autoimmune setting and identifies the Pik3ip1/Hif1alpha/glycolysis axis as a potential therapeutic target for treatment of autoimmune diseases. |
